Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.35 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30323777 | 0.79 | NAMPT (0.50) | NAMPTPDE10ATGFBR1TGFBR2ADORA2A | |
| SCHEMBL30323645 | 0.75 | NAMPT (0.60) | NAMPTPDE10A | |
| SCHEMBL30943174 | 0.74 | PDE10A (0.51) | NAMPTPDE10A | |
| SCHEMBL20031271 | 0.73 | KDM4E (0.40) | HTT | |
| SCHEMBL24042557 | 0.72 | NAMPT (1.00) | NAMPT | |
| SCHEMBL26131533 | 0.71 | AKR1B1 (0.41) | — | |
| SCHEMBL23320500 | 0.71 | NAMPT (0.58) | NAMPTPDE10ATGFBR1TGFBR2 | |
| SCHEMBL25183446 | 0.70 | PIK3CD (0.41) | — | |
| SCHEMBL13267543 | 0.70 | ALDH1A1 (0.41) | — | |
| SCHEMBL13245188 | 0.70 | SRD5A2 (0.38) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12263159-B2 | Fused ring compound having urea structure | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240285597-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2024-08-29 | — | — | US | disclosed |
| CN-112654608-B | Fused ring compound having urea structure | 桑福德伯纳姆普利斯医学发现研究所 | 2024-05-07 | — | — | CN | disclosed |
| EP-3818053-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12263159-B2 | Fused ring compound having urea structure | NAMPT, NME4, NDUFAB1 | NAMPT 1/4885PDE10A 668/4885TGFBR1 3429/4885 |
| US-20240285597-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | NAMPT, NME4, NDUFAB1 | NAMPT 1/4885PDE10A 668/4885TGFBR1 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.